Enanta Pharmaceuticals (9EP) Price & Analysis

0 Followers

9EP Stock Chart & Stats

€12.00

-€0.20(-1.77%)

At close: Jul 24 4:00 PM EDT

€12.00

-€0.20(-1.77%)

Day’s Range― - ―

52-Week Range€8.65 - €14.20

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€278.37M

Enterprise Value€416.67M

Total Cash (Recent Filing)€189.51M

Total Debt (Recent Filing)€55.66M

Price to Earnings (P/E)―

Beta1.11

Next Earnings

Nov 16, 2026

EPS Estimate

-0.65

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.41

Shares Outstanding29,125,402

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.10

Price to Book (P/B)3.95

Price to Sales (P/S)3.91

P/FCF Ratio-7.94

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€17.86

Price Target Upside48.81% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-1.96

Revenue Forecast (FY)€53.94M

Bulls Say, Bears Say

Bulls Say

Very High Gross MarginA roughly 98% gross margin shows that Enanta’s offerings can generate substantial value after direct costs. If its pipeline produces commercially viable medicines or partnered products, this underlying economics could support attractive contribution margins, even though current operating expenses still exceed gross profit.

Improved LeverageThe sharp reduction in debt and return to a much lower debt-to-equity level improve financial flexibility relative to prior periods. Positive equity and less leverage give Enanta more capacity to fund development, manage volatility, and pursue partnerships while reducing balance-sheet pressure.

Losses Are NarrowingAlthough Enanta remains unprofitable, the narrowing of losses suggests some improvement in the relationship between revenue and operating spending. Continued progress could extend its cash runway and reduce the financing burden, making future pipeline investment more sustainable if the trend persists.

Bears Say

Persistent Operating LossesDeep operating and net losses indicate that Enanta’s current business activities do not yet cover its cost base. Sustained unprofitability can erode equity, constrain investment in research programs, and increase dependence on successful partnerships, milestones, or future external financing.

Ongoing Cash BurnNegative operating and free cash flow show that Enanta is not currently self-funding its operations. Even with improved burn versus earlier periods, continued cash consumption can reduce financial flexibility and make advancement of its pipeline dependent on reserves, partnerships, or capital access.

Patent Ruling Weakens IP LeverageThe European patent invalidation removes a potential source of enforcement leverage and licensing proceeds connected with Paxlovid. It also highlights the difficulty of monetizing disputed intellectual property against a large competitor, weakening the value of this potential revenue opportunity.

Enanta Pharmaceuticals News

Enanta announces retirement of CEO Luly, appoints Kieffer as COO

Enanta (ENTA) Pharmaceuticals announces that Jay Luly, Ph.D., age 70, will retire as President and Chief Executive Officer,...

4d ago

ENTA

Enanta announces first patient dosed in Resolve Phase 2b/3 trial

Enanta (ENTA) Pharmaceuticals announced that the first patient has been dosed in RESOLVE, its global Phase 2b/3 clinical...

6d ago

ENTA

Enanta Hit by UPC Ruling Invalidating Key Patent

Enanta Pharmaceuticals ( ($ENTA) ) has issued an update. Enanta Pharmaceuticals has been pursuing a patent infringement case...

2d ago

ENTA

Enanta Pharmaceuticals Announces CEO Retirement and COO Appointment

The latest announcement is out from Enanta Pharmaceuticals ( ($ENTA) ). On October 28, 2026, Enanta Pharmaceuticals announced...

4d ago

ENTA

Enanta Pharmaceuticals Flags Ongoing Uncertainty as 2025 Risk Factors Continue to Shape 2026 Outlook

Enanta Pharmaceuticals (ENTA) has disclosed a new risk, in the Regulation category. Enanta Pharmaceuticals faces broad and ongoing...

3M ago

ENTA

Enanta reports Q3 EPS (67c), consensus (51c)

Reports Q3 revenue $14.4M, consensus $16.8M. “During the quarter, we continued to build momentum across both our RSV...

3M ago

ENTA

Is ENTA a Buy, Before Earnings?

Enanta Pharmaceuticals (ENTA) is scheduled to report 3rd quarter earnings on 08/10/2026. Regarding Q3 estimates, Wall Street analysts...

3M ago

ENTA

Enanta Pharmaceuticals Establishes Flexible At-The-Market Offering

An update from Enanta Pharmaceuticals ( ($ENTA) ) is now available. On July 2, 2026, Enanta Pharmaceuticals entered...

4M ago

ENTA

Enanta Faces Patent Setback in Paxlovid Litigation

The latest announcement is out from Enanta Pharmaceuticals ( ($ENTA) ). Enanta Pharmaceuticals, Inc. reported that on June...

4M ago

ENTA

Enanta announces European Commission approval of Maviret

Enanta (ENTA) announced that the European Commission has approved Maviret, an oral pangenotypic direct-acting antiviral therapy, for the...

4M ago

ENTA

Enanta Advances RSV Antiviral Zelicapavir to Registrational Trial

Enanta Pharmaceuticals ( ($ENTA) ) just unveiled an update. On June 18, 2026, Enanta announced it will advance...

5M ago

ENTA

Enanta to advance zelicapavir into registrational Phase 2b/3 clinical trial

Enanta (ENTA) Pharmaceuticals is advancing zelicapavir into a registrational Phase 2b/3 clinical trial in adults at high risk...

5M ago

ENTA

Enanta reports Q2 EPS (45), consensus (49c)

Reports Q2 revenue $17.2M, consensus $17.09M. “Since the inception of our immunology portfolio targeting type 2 diseases, our...

6M ago

ENTA

ENTA Earnings this Week: How Will it Perform?

Enanta Pharmaceuticals (ENTA) is scheduled to report 2nd quarter earnings on 05/11/2026. Regarding Q2 estimates, Wall Street analysts...

6M ago

ENTA

9EP FAQ

What was Enanta Pharmaceuticals’s price range in the past 12 months?

Enanta Pharmaceuticals lowest stock price was €8.65 and its highest was €14.20 in the past 12 months.

What is Enanta Pharmaceuticals’s market cap?

Enanta Pharmaceuticals’s market cap is €278.37M.

When is Enanta Pharmaceuticals’s upcoming earnings report date?

Enanta Pharmaceuticals’s upcoming earnings report date is Nov 16, 2026 which is in 15 days.

How were Enanta Pharmaceuticals’s earnings last quarter?

Enanta Pharmaceuticals released its earnings results on Aug 10, 2026. The company reported -€0.598 earnings per share for the quarter, missing the consensus estimate of -€0.455 by -€0.143.

Is Enanta Pharmaceuticals overvalued?

According to Wall Street analysts Enanta Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Enanta Pharmaceuticals pay dividends?

Enanta Pharmaceuticals does not currently pay dividends.

What is Enanta Pharmaceuticals’s EPS estimate?

Enanta Pharmaceuticals’s EPS estimate is -0.65.

How many shares outstanding does Enanta Pharmaceuticals have?

Enanta Pharmaceuticals has 29,125,402 shares outstanding.

What happened to Enanta Pharmaceuticals’s price movement after its last earnings report?

Enanta Pharmaceuticals reported an EPS of -€0.598 in its last earnings report, missing expectations of -€0.455. Following the earnings report the stock price went down -2.521%.

Which hedge fund is a major shareholder of Enanta Pharmaceuticals?

Currently, no hedge funds are holding shares in DE:9EP

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Enanta Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-61.84%

Trailing 12-Months

Asset Growth

-1.38%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.

Enanta Pharmaceuticals (9EP) Earnings & Revenues

Historic Earnings Reports

9EP Stock 12 Month Forecast

Average Price Target

€17.86

▲(48.81% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"€7","18":"€18","9.75":"€9.75","12.5":"€12.5","15.25":"€15.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17.8569994,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€17.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.8569994,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€17.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.8569994,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€17.86</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,9.75,12.5,15.25,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.3,11.80438456923077,12.308769138461539,12.813153707692308,13.317538276923077,13.821922846153846,14.326307415384615,14.830691984615385,15.335076553846154,15.839461123076923,16.343845692307692,16.84823026153846,17.35261483076923,{"y":17.8569994,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.3,11.80438456923077,12.308769138461539,12.813153707692308,13.317538276923077,13.821922846153846,14.326307415384615,14.830691984615385,15.335076553846154,15.839461123076923,16.343845692307692,16.84823026153846,17.35261483076923,{"y":17.8569994,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.3,11.80438456923077,12.308769138461539,12.813153707692308,13.317538276923077,13.821922846153846,14.326307415384615,14.830691984615385,15.335076553846154,15.839461123076923,16.343845692307692,16.84823026153846,17.35261483076923,{"y":17.8569994,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.95,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.6,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.2,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.1,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.7,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.8,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.9,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.8,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.6,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.3,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >